ATE335502T1 - Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen - Google Patents

Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen

Info

Publication number
ATE335502T1
ATE335502T1 AT00920987T AT00920987T ATE335502T1 AT E335502 T1 ATE335502 T1 AT E335502T1 AT 00920987 T AT00920987 T AT 00920987T AT 00920987 T AT00920987 T AT 00920987T AT E335502 T1 ATE335502 T1 AT E335502T1
Authority
AT
Austria
Prior art keywords
arthritis
treatment
glucose
phosphate isomerase
diagnostic
Prior art date
Application number
AT00920987T
Other languages
English (en)
Inventor
Christophe Benoist
Isao Matsumoto
Anne-Sophie Korganow
Diane Mathis
Mariana Maccioni
Hong Ji
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE335502T1 publication Critical patent/ATE335502T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00920987T 1999-04-22 2000-04-21 Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen ATE335502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13073099P 1999-04-22 1999-04-22

Publications (1)

Publication Number Publication Date
ATE335502T1 true ATE335502T1 (de) 2006-09-15

Family

ID=22446051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920987T ATE335502T1 (de) 1999-04-22 2000-04-21 Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen

Country Status (8)

Country Link
EP (1) EP1171157B1 (de)
JP (2) JP4633265B2 (de)
AT (1) ATE335502T1 (de)
CA (1) CA2370867C (de)
DE (1) DE60029942T2 (de)
DK (1) DK1171157T3 (de)
ES (1) ES2269127T3 (de)
WO (1) WO2000064469A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
WO2005072290A2 (en) 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
CA2567429C (en) * 2004-05-31 2013-04-23 Japan Science And Technology Agency Restless legs syndrome/periodic appendicular dyskinesia model animal
CN105223356A (zh) * 2015-10-20 2016-01-06 常州英赞美科生物科技有限公司 Gpi胶乳增强免疫比浊法体外定量测定诊断试剂盒
WO2025073856A1 (en) 2023-10-04 2025-04-10 Xenothera Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720885B2 (ja) * 1985-09-27 1995-03-08 帝人株式会社 単純ヘルペスウイルス感染症の予防又は治療剤
US5675060A (en) * 1994-05-19 1997-10-07 Institut National De La Sante Et De La Recherche Medicale Transgenic arthritic mice expressing a T-cell receptor transgene
JPH08245397A (ja) * 1995-01-13 1996-09-24 Ajinomoto Co Inc グルコース−６−リン酸イソメラーゼ阻害剤からなる自己分泌型運動因子活性阻害剤
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
AU9594598A (en) * 1997-10-02 1999-04-27 Millennium Pharmaceuticals, Inc. Modulation of lerk-2-mediated cell adhesion
AUPP589398A0 (en) * 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof

Also Published As

Publication number Publication date
JP2010252795A (ja) 2010-11-11
WO2000064469A3 (en) 2001-05-25
EP1171157B1 (de) 2006-08-09
CA2370867A1 (en) 2000-11-02
JP4633265B2 (ja) 2011-02-16
DE60029942D1 (de) 2006-09-21
WO2000064469A2 (en) 2000-11-02
EP1171157A2 (de) 2002-01-16
ES2269127T3 (es) 2007-04-01
JP2002544474A (ja) 2002-12-24
DK1171157T3 (da) 2006-10-30
JP5231477B2 (ja) 2013-07-10
CA2370867C (en) 2011-12-06
DE60029942T2 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE302278T1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ATE438716T1 (de) Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
ATE159982T1 (de) Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
DE3486262D1 (de) Verfahren zur Herstellung eines monoklonalen Antikörpers mit Spezifizität für vernetzte Fibrinderivate und ein Testverfahren mittels dieses Antikörpers.
ATE338818T1 (de) Verfahren zur diagnose des glaukoms
NO20025354L (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
CA2239208A1 (en) Treatment and diagnosis of infections due to helicobacter pylori
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
ATE547536T1 (de) Lmna-gen und seine beteiligung an progeria hutchinson-gilford (hgps) und arteriosklerose
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
ATE335502T1 (de) Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen
DK1181366T4 (da) Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder
DE3786090D1 (de) Monoklonale antikoerper und verfahren zum nachweis von pathogenen pilzen.
ATE354095T1 (de) Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
ATE557277T1 (de) Verfahren zur diagnose von endometriose mittels tfpi-2 protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1171157

Country of ref document: EP